SS Innovations Develops New Instruments to Advance Robotic Surgery in Large, Underserved Patient Segments, including Pediatric and Cardiac Markets

Rhea-AI Summary

SS Innovations (Nasdaq: SSII) announced completion of five new 5-millimeter surgical instruments for clinical use with its SSi Mantra robotic system, targeting pediatric, cardiac, and head-and-neck procedures. The instruments are a spatula cautery, hook cautery, needle driver, bipolar forceps, and grasping forceps.

As of Dec 31, 2025, the SSi Mantra installed base totaled 168 systems across 153 hospitals, with more than 7,800 procedures performed, including over 120 telesurgeries and more than 400 cardiac procedures. The company says the smaller instruments aim to expand robotic access for children and other patients with small anatomical structures.

Positive

• Five 5-mm instruments completed for clinical use
• Designed for pediatric, cardiac, and head-and-neck procedures
• Installed base: 168 systems as of Dec 31, 2025
• Procedure volume: 7,800+ procedures to date, incl. >400 cardiac

Negative

• Limited international footprint: only 12 systems deployed outside India

Key Figures

Current price $5.42 Before publication of Jan 6, 2026 news

52-week range $3.015–$22.42 Pre-news trading range

Installed SSi Mantra systems 168 systems Cumulative installed base as of Dec 31, 2025

Hospitals using SSi Mantra 153 hospitals Cumulative adopter institutions as of Dec 31, 2025

Cumulative procedures More than 7,800 procedures Performed on SSi Mantra, including telesurgeries and cardiac

Global pediatric care gap 1.7 billion children Children and adolescents lacking easy access to surgical care

Children under five affected 390 million children Under-fives in lower- and middle-income countries without timely surgery

Q3 2025 revenue $12.8M Third quarter 2025, up 192.5% year over year

Market Reality Check

$5.77 Last Close

Volume Volume 63,319 is below the 20-day average of 84,242 (about 0.75x normal activity). normal

Technical Price at $5.42 is trading below the 200-day MA of $7.18 and far under the $22.42 52-week high.

Peers on Argus

SSII fell 4.07% while key peers were mixed: several like IART and NVCR showed gains, AHCO and BBNX were modestly positive, and ESTA declined, pointing to stock-specific pressure rather than a unified sector move.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Dec 08	Regulatory filing update	Positive	+0.6%	FDA 510(k) submission and EU CE marking timeline for SSi Mantra.
Nov 06	Technology milestone	Positive	-2.3%	First telesurgery using SSi Mantra Tele Surgeon Console completed.
Oct 28	Earnings report	Positive	-0.9%	Q3 2025 revenue growth and system sales with ongoing net loss.
Oct 21	Investor conferences	Positive	-0.7%	Announcement of participation in UBS and Stifel healthcare conferences.
Oct 02	Regulatory strategy	Positive	-8.6%	Human factors study completion and plan for FDA 510(k) in H1 2026.

Pattern Detected

Recent history shows SSII often trading lower on otherwise positive operational and regulatory updates, with only one modestly positive reaction in the last five news events.

Recent Company History

Over the past few months, SSII has reported strong operational progress, including a Q3 2025 revenue ramp to $12.8M, ongoing losses and going-concern language in its 10-Q, and expansion of the SSi Mantra installed base across multiple countries. Regulatory steps progressed via a 510(k) submission and human factors work, while the company also highlighted a first telesurgery using its Tele Surgeon Console. Despite these milestones, most prior news days saw muted or negative price reactions, providing context for how markets have treated today’s new instrument launch.

Market Pulse Summary

This announcement highlights the launch of five new 5-millimeter instruments tailored to pediatric, cardiac, and head and neck robotic surgery, expanding the SSi Mantra system’s reach. With an installed base of 168 systems across 153 hospitals and more than 7,800 procedures performed, it builds on recent growth and regulatory progress. Investors may watch future procedure volumes, international adoption, and updates on FDA and CE-mark pathways to gauge the impact of these instruments.

Key Terms

telesurgeries technical

"more than 7,800 surgical procedures have been performed, including over 120 telesurgeries"

Surgery performed by a clinician who is physically distant from the patient, using robotic instruments, real‑time video and sensors controlled over high‑speed networks; think of a surgeon using a precise game controller to operate tools in another location. Investors care because telesurgeries can expand patient access, shift where care happens, and create new markets for medical robots, software and communications, while also carrying regulatory, reimbursement and liability uncertainties that affect adoption and returns.

coronary artery bypass surgery medical

"such as the internal mammary artery during robotic coronary artery bypass surgery."

Coronary artery bypass surgery is an operation that creates a new route for blood to flow around blocked heart arteries by grafting a healthy blood vessel from elsewhere in the body. Think of it as installing a detour around a traffic jam to restore normal flow. Investors care because the procedure affects healthcare spending, hospital demand, medical device and drug markets, and can change a company’s revenues, costs, and liability exposure tied to cardiac care.

internal mammary artery medical

"which often involves small structures, such as the internal mammary artery during robotic"

A blood vessel running along the inside of the chest wall that supplies the chest and breast area; surgeons commonly use it as a durable “spare hose” to reroute blood around blocked heart arteries during bypass surgery. Investors care because how and how often this vessel is used affects demand for cardiac surgical devices, clinical outcomes, hospital costs and reimbursement, and can influence regulatory decisions and adoption of new treatments and technologies.

bipolar forceps medical

"include a spatula cautery, hook cautery, needle driver, bipolar forceps, and grasping forceps."

Bipolar forceps are handheld surgical instruments with tweezer-like tips that pass a controlled electric current between the two prongs to clamp and seal small blood vessels, helping surgeons stop bleeding during procedures. Investors watch them because they are common, often disposable or paired with costly generators, and their clinical performance, regulatory clearance and hospital buying patterns directly affect medical device sales, recurring revenue and profit margins.

surgical robotic system technical

"to be incorporated into the SSi Mantra surgical robotic systemFORT LAUDERDALE"

A surgical robotic system is a hospital-grade machine that combines robotic arms, high-resolution cameras and control software to help surgeons perform operations with smaller cuts, steadier movements and better views. Investors care because these systems can change how often and how profitably procedures are done: hospitals buy expensive equipment, pay ongoing fees for instruments and service, and may attract more patients, making adoption, approvals and recurring revenue important signals of financial upside.

AI-generated analysis. Not financial advice.

Smaller 5-millimeter instruments to be incorporated into the SSi Mantra surgical robotic system

FORT LAUDERDALE, Fla., Jan. 06, 2026 (GLOBE NEWSWIRE) -- SS Innovations International, Inc. (the “Company” or “SS Innovations”) (Nasdaq: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced that the Company has completed the development of five new 5-millimeter surgical instruments for clinical use across multiple specialties, including pediatric, cardiac, and head and neck surgery, among other procedures involving smaller anatomical structures.

The newly developed 5-millimeter surgical instruments include a spatula cautery, hook cautery, needle driver, bipolar forceps, and grasping forceps.

       
Dr. Vishwa Srivastava, the Company’s Chief Executive Officer for Asia Pacific, commented, “We developed several new smaller instruments designed to benefit critical surgical robotic procedures across multiple specialties, including pediatric, cardiac, and head and neck. Our innovative 5-millimeter instruments, combined with our advanced, cost-effective SSi Mantra surgical robotic system, show great promise for supporting the large population of pediatric patients left behind each year. Globally, 1.7 billion children and adolescents lack easy access to critical surgical care, which can play a significant role in preventing disability and death.¹ It has been reported that more than 390 million children under the age of five in lower- and middle-income countries do not receive timely intervention with safe and affordable surgical care.² Unfortunately, to date most robotic surgeries have been geared towards the adult population. We aim to make robotic surgery more accessible to pediatric patients with new, smaller surgical instruments.”  

Dr. Srivastava concluded, “In addition, our 5-millimeter instruments can benefit cardiac surgery, which often involves small structures, such as the internal mammary artery during robotic coronary artery bypass surgery. Furthermore, our new robotic instruments can help perform critical tasks during head and neck procedures, which entail tight working space and quite small structures. Moving forward, we will continue to focus on developing differentiated surgical robotic technologies, such as these instruments, for the benefit of a larger segment of patients globally.”

As of December 31, 2025, the cumulative installed base of the SSi Mantra totaled 168 systems, including 12 systems deployed across nine countries outside of India. To date, 153 hospitals have installed the SSi Mantra, and more than 7,800 surgical procedures have been performed, including over 120 telesurgeries and more than 400 cardiac procedures.

¹ Mullapudi, Bhargava, et al. “Estimates of Number of Children and Adolescents without Access to Surgical Care.” Bulletin of the World Health Organization, vol. 97, no. 4, 2019, pp. 254–58. PubMed Central, https://pmc.ncbi.nlm.nih.gov/articles/PMC6438256/.

² Wadhwani, Vidhi, and Siddhesh Zadey. “How Pediatric Surgery Could Help India Reach Its Development Goals.” Think Global Health, 14 Mar. 2024, https://www.thinkglobalhealth.org/article/how-pediatric-surgery-could-help-india-reach-its-development-goals.

About SS Innovations
SS Innovations International, Inc. (Nasdaq: SSII) develops innovative surgical robotic technologies with a vision to make the benefits of robotic surgery affordable and accessible to a larger segment of the global population. The Company’s product range includes its proprietary “SSi Mantra” surgical robotic system and its comprehensive suite of “SSi Mudra” surgical instruments, which support a variety of robotic surgical procedures including cardiac surgery. An American company headquartered in India, SS Innovations plans to expand the global presence of its technologically advanced, user-friendly, and cost-effective surgical robotic solutions. Visit the Company’s website at ssinnovations.com or LinkedIn for more information and updates.

About the SSi Mantra
The SSi Mantra surgical robotic system is a user-friendly, modular, multi-arm system with many advanced technology features, including: 3 to 5 modular robotic arms, an open-faced ergonomic surgeon command center, a large 3D 4K monitor, a touch panel monitor for all patient related information display, a virtual real-time image of the robotic patient side arm carts, and the ability for superimposition of 3D models of diagnostic imaging. A vision cart provides the table-side team with the same magnified 3D 4K view as the surgeon to provide better safety and efficiency. The SSi Mantra utilizes over 40 different types of robotic endo-surgical instruments to support different specialties, including cardiac surgery. The SSi Mantra has been clinically validated in India in more than 100 different types of surgical procedures.

Forward Looking Statements
This press release may contain statements that are not historical facts and are considered forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. The words “anticipate,” “assume,” “believe,” “estimate,” “expect,” “will,” “intend,” “may,” “plan,” “project,” “should,” “could,” “seek,” “designed,” “potential,” “forecast,” “target,” “objective,” “goal,” or the negatives of such terms or other similar expressions to identify such forward-looking statements. These statements relate to future events or SS Innovations’ future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements.

Investor Contact:
The Equity Group        
Kalle Ahl, CFA                
T: (303) 953-9878        
kahl@theequitygroup.com

Devin Sullivan, Managing Director
T: (212) 836-9608
dsullivan@theequitygroup.com

Media Contact:
RooneyPartners LLC
Kate Barrette
T: (212) 223-0561
kbarrette@rooneypartners.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/2f60846c-4568-4935-a282-63e5d405d75e

FAQ

What 5-millimeter instruments did SS Innovations (SSII) develop?

SS Innovations developed a spatula cautery, hook cautery, needle driver, bipolar forceps, and grasping forceps for the SSi Mantra system.

How many SSi Mantra systems were installed as of Dec 31, 2025 for SSII?

The company reported a cumulative installed base of 168 SSi Mantra systems as of Dec 31, 2025.

How many procedures has SS Innovations' SSi Mantra performed through Dec 31, 2025?

SS Innovations reported more than 7,800 procedures, including over 120 telesurgeries and >b>400 cardiac procedures.

Will SSII's 5-mm instruments support pediatric surgeries?

The company states the 5-mm instruments are designed to expand robotic access to pediatric surgeries and other procedures involving smaller anatomy.

How widely are SSi Mantra systems deployed internationally for SSII?

As of Dec 31, 2025, 12 systems were deployed across nine countries outside India.

Which surgical specialties could benefit from SSII's new 5-mm instruments?

The instruments target pediatric, cardiac, and head-and-neck procedures and other operations involving small anatomical structures.